Design efficiency in dose finding studies

Abstract An investigator about to undertake a dose finding study can choose from rival methods. In selecting any method he or she may have certain properties in mind. Our purpose here is to present an approach to evaluating rival methods which can help provide guidance to the investigator. The idea is to determine which of any given number of competing dose finding studies has a superior performance in given circumstances. The approach is centered around three components. The first of these is simply a very broad class of potential dose–toxicity relations, of which current examples in the literature can be seen to be special cases. The second component, for some given situation or class of situations, is an optimal method, not one that we can necessarily apply in practice, but one that provides a gold standard, beyond which improvements are not generally possible. The third component is a class of efficiency measures which indicate how close to the optimal method is the performance of any given method. We are then able to compare rival approaches both in a relative and absolute sense.

[1]  J O'Quigley,et al.  Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.

[2]  Ethan Reiner,et al.  A stopping rule for the continual reassessment method , 1998 .

[3]  J G Ibrahim,et al.  Longitudinal design for phase I clinical trials using the continual reassessment method. , 2000, Controlled clinical trials.

[4]  E. Eisenhauer,et al.  Multinomial phase II cancer trials incorporating response and early progression. , 1999, Journal of biopharmaceutical statistics.

[5]  Nancy Flournoy,et al.  Random Walks for Quantile Estimation , 1994 .

[6]  J O'Quigley,et al.  Continual reassessment method: a likelihood approach. , 1996, Biometrics.

[7]  John O'Quigley,et al.  Non-parametric optimal design in dose finding studies. , 2002, Biostatistics.

[8]  Thomas M Braun,et al.  The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. , 2002, Controlled clinical trials.

[9]  S. Møller,et al.  An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. , 1995, Statistics in medicine.

[10]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[11]  S. Gupta,et al.  Statistical decision theory and related topics IV , 1988 .

[12]  J. Whitehead,et al.  Bayesian decision procedures with application to dose-finding studies , 1997 .

[13]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[14]  P F Thall,et al.  A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. , 1998, Biometrics.

[15]  D. Faries,et al.  Practical modifications of the continual reassessment method for phase I cancer clinical trials. , 1994, Journal of biopharmaceutical statistics.

[16]  Jeffrey R. Eisele,et al.  A Curve‐Free Method for Phase I Clinical Trials , 2000, Biometrics.

[17]  T A Gooley,et al.  Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. , 1994, Controlled clinical trials.

[18]  S. Piantadosi,et al.  Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.

[19]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[20]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.